Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489339 | 0.87 | SLC2A1 (0.41) | SLC2A1DAO | |
| SCHEMBL4472791 | 0.87 | SLC2A1 (0.46) | SLC2A1DAOMAPTTDP2 | |
| SCHEMBL4493394 | 0.83 | SLC2A1 (0.52) | SLC2A1MAPT | |
| SCHEMBL4483281 | 0.82 | SLC2A1 (0.44) | SLC2A1 | |
| SCHEMBL4491224 | 0.77 | DAO (0.34) | SLC2A1DAOMAPT | |
| SCHEMBL4485647 | 0.77 | HSD11B1 (0.35) | SLC2A1DAOMAPT | |
| SCHEMBL4486516 | 0.77 | ADORA2A (0.41) | SLC2A1 | |
| SCHEMBL4464654 | 0.76 | ADORA2A (0.39) | SLC2A1MAPT | |
| SCHEMBL4476390 | 0.76 | SLC2A1 (0.56) | SLC2A1 | |
| SCHEMBL4464123 | 0.76 | SLC2A1 (0.41) | SLC2A1DAOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | claimed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | claimed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1858876-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094799-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | SLC2A1 2278/4885DAO 2428/4885MAPT 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.